Pharmaceutical regulation in Kenya is anchored by the Pharmacy and Poisons Board, operating within a detailed statutory framework. The Pharmacy and Poisons Board (PPB) operates under the Pharmacy and Poisons Act (Cap 244) and is responsible for registering pharmaceutical products, licensing manufacturing facilities and pharmacies, approving clinical trials, and controlling importation and distribution. For any business bringing a medicine, vaccine, herbal remedy, or other health product to the Kenyan market, understanding how the PPB exercises this authority, and the practical steps required to comply with it, is the difference between a smooth market entry and a registration refusal, a seizure, or a fine that sets a launch back by months.

The Legal Basis for the Board’s Authority in Pharmaceutical Regulation in Kenya

The Pharmacy and Poisons Act (Cap 244) establishes the PPB as a body corporate mandated to regulate the practice of pharmacy and the manufacture, distribution, sale, and use of drugs and poisons in Kenya. Section 3A of the Act empowers the Board to formulate guidelines for regulating health products and technologies, grant or withdraw marketing authorisation, and prescribe the standards new products must meet before reaching patients or consumers. Day-to-day registration and licensing decisions now sit under the Pharmacy and Poisons (Registration of Health Products and Technologies) Rules, 2022, gazetted on 17 June 2022, which set out the application procedure, documentation requirements, and grounds on which the Board may refuse or revoke registration.

Registering a Health Product or Technology

Under the 2022 Rules, no person may import, manufacture, or sell a health product or technology in Kenya unless it has first been registered with the PPB. The application is made on Form 1 in the First Schedule to the Rules and must be accompanied by a technical dossier covering the chemical and pharmaceutical composition of the product, pre-clinical and, where applicable, clinical pharmacological and toxicological data, evidence that the manufacturer complies with Good Manufacturing Practice standards as determined by the Board, and details of any existing registration of the product with another recognised regulatory authority. The Board assesses applications against the Common Technical Document format set out in its Compendium of Guidelines on Medicines Evaluation and Registration, and may request a certificate of analysis from a WHO-prequalified quality control laboratory before issuing a certificate of registration.

Registration is not a one-time event. The holder of a certificate of registration remains responsible for the product’s labelling, packaging, advertising, and pharmacovigilance system for as long as that product stays on the Kenyan market, and registrations are subject to periodic renewal and variation procedures rather than standing indefinitely once granted.

Foreign Manufacturers and Local Technical Representatives

Where the applicant is not a Kenyan citizen, or is a company incorporated outside Kenya, the 2022 Rules require the appointment of a Local Technical Representative (LTR) and submission of the agreement appointing that representative as part of the application. The PPB has separately published Guidelines for the Establishment and Operation of Pharmaceutical Scientific Offices in Kenya, reflecting the growing reliance of marketing authorisation holders and LTRs on structured local arrangements for regulatory support rather than informal agency relationships. For a foreign pharmaceutical or medical technology company entering the Kenyan market, getting the LTR relationship right at the outset, with clear contractual responsibility for pharmacovigilance, recall coordination, and regulatory correspondence, is one of the more commonly underestimated steps in market entry.

Manufacturing, Wholesale, and Premises Licensing

Separately from product registration, anyone manufacturing, wholesaling, or operating pharmacy premises in Kenya needs the relevant PPB licence for that activity. A pharmacy business cannot lawfully operate unless its premises hold a current approval and every person with a financial interest in the business is a registered pharmacist or enrolled pharmaceutical technologist. A wholesale dealer’s licence is issued at the Board’s discretion where it is satisfied that doing so is in the public interest, and a refusal or revocation may be appealed to the Cabinet Secretary, whose decision is final. Manufacturing facilities must additionally demonstrate Good Manufacturing Practice compliance as a condition of both initial licensing and the assessment of any product registration tied to that facility.

Importation Controls

Importing a drug, Part I poison, cosmetic, herbal product, or medical device into Kenya generally requires an import licence issued by the Board, and importing without one is an offence in its own right, separate from any defect in the underlying product registration. The Pharmacy and Poisons Rules permit the Board to issue such licences on payment of the prescribed fee, calculated by reference to the freight-on-board value of the consignment, to specified categories of importers. Businesses structuring supply chains into Kenya should treat import licensing as a distinct compliance workstream from product registration, since the two run on different timelines and the absence of either one can hold a shipment at the border regardless of the other being in order.

Clinical Trials and Pharmacovigilance

Where a registration dossier relies on clinical data generated locally, the Board’s approval of the underlying clinical trial protocol, and documented evidence of properly witnessed informed consent from participants, forms part of what the Board scrutinises in the registration file. Once a product is on the market, pharmacovigilance obligations do not end at the point of sale: the Act defines pharmacovigilance to include the detection, assessment, and prevention of adverse reactions and other drug-related problems identified through post-market surveillance, and the Board can use safety signals identified after registration as grounds to vary, suspend, or withdraw a product’s authorisation.

Advertising and Promotion Restrictions

Part IV of the Act imposes specific restrictions on how pharmaceutical products may be advertised. Advertisements referring to a drug, medicine, or medical appliance in terms the Board considers extravagant, or bearing little relation to the actual pharmacological properties of the product, are prohibited under section 39, with further outright prohibitions on advertisements relating to certain diseases and to abortion under sections 37 and 38. A first contravention of sections 36 to 39 carries a fine of up to KES 20,000 or up to one year’s imprisonment, or both, rising to a fine of up to KES 30,000 or two years’ imprisonment, or both, for a subsequent conviction. Marketing and medical affairs teams operating in Kenya should treat PPB advertising clearance as a standing item in their promotional review process, not an afterthought addressed once a campaign is ready to launch.

Enforcement Powers and Penalties

The Board’s inspectors have statutory powers to enter and search premises, retain and dispose of goods seized in the course of an investigation, and demand production of licences and books for inspection; obstructing an authorised officer in the exercise of these powers is itself an offence. Penalties elsewhere in the Act scale with the seriousness of the underlying conduct. Practising as a pharmacist without registration, for example, carries a fine of up to KES 30,000 or three years’ imprisonment, while contravening the Board’s powers to prohibit or control certain medicines carries a fine of up to KES 1,000,000 or imprisonment for up to a year, reflecting how much more seriously the Act treats circumvention of the Board’s product-level controls compared with administrative or labelling lapses.

Practical Compliance Guidance

For a business bringing a health product to Kenya for the first time, the realistic sequence rarely runs “register, then sell.” It typically runs in parallel: securing the LTR relationship and reviewing the technical dossier against the Board’s current Compendium and the 2022 Registration Rules, lining up an import licence application alongside the registration application rather than after it is granted, and building advertising and labelling review into the launch timeline well before commercial materials are finalised. The PPB has been actively engaging industry, including through the Kenya Association of Pharmaceutical Industry and the Medical Technology Industry Association of Kenya, on registration, renewal, and trade facilitation issues through 2026, so businesses in this space should expect procedural detail to keep evolving and budget for periodic compliance review rather than treating an initial registration as the end of the work.

Clay & Associates Advocates advises pharmaceutical, medical device, and health technology businesses on PPB registration strategy, local technical representative arrangements, import licensing, and advertising compliance review. If your business is entering or already operating in Kenya’s regulated health products market, we can help you map the registration pathway that applies to your specific product category before it becomes a bottleneck at the border or a compliance gap the Board flags after the fact.

Bringing a pharmaceutical product to the Kenyan market? Contact Clay & Associates Advocates for a PPB registration strategy session. Book a Consultation

Related reading: Medical Devices Regulation in Kenya | Healthcare Regulation in Kenya | KEBS Standards Compliance

For expert legal guidance on this matter, consult our life sciences and healthcare legal services team at Clay & Associates Advocates. We advise healthcare businesses, investors, and practitioners across Kenya on Life Sciences and Healthcare matters from our offices at Nextgen Mall, Nairobi.